Connect Biopharma Holdings (CNTB) Non-Current Assets (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Non-Current Assets for 7 consecutive years, with $5.0 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Assets rose 2.35% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (up 6.28% YoY) and the FY2025 annual result came in at $5.1 million, up 19.04% from the prior year.
• Non-Current Assets retreated to $5.0 million in Q1 2026 per CNTB's latest filing, from $5.1 million in the prior quarter.
• Over the last five years, Non-Current Assets for CNTB reached as high as $37.6 million in Q2 2022 and fell as low as $4.3 million in Q4 2024.
• A 5-year average of $9.1 million and a median of $5.0 million in 2025 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets slumped 84.29% — and 2025, when it gained 19.04%.
• Year by year, Non-Current Assets stood at $17.9 million in 2022, then sank by 72.99% to $4.8 million in 2023, then declined by 10.35% to $4.3 million in 2024, then climbed by 19.04% to $5.1 million in 2025, then dropped by 1.94% to $5.0 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $5.0 million, $5.1 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.